Key Takeaways
- Guidance raised on Zoetis and FX: Full-year revenue growth guidance lifted from mid-teens to high teens, driven by a 10-year Zoetis commercial manufacturing deal worth up to US$500 Mn and a weaker rupee.
- Underlying growth strong, headline muted: Reported revenue grew 8% YoY, but excluding the high base of Remdesivir sales in Q1 FY22, underlying growth was ~30%.
- PAT down on tough comp: PAT declined 4% YoY to ₹74 Cr because the prior-year quarter included one-off Remdesivir sales; no such sales were recorded in Q1 FY23.
- Zoetis deal unlocks biologics pathway: The Librela® agreement gives Syngene a route to FDA and EMA regulatory approvals anticipated later this year, with revenue starting in H2 FY23 and building gradually.
- What to watch next quarter: The pace of Zoetis-related revenue ramp once regulatory approvals are secured, and whether the underlying ~30% ex-Remdesivir growth momentum sustains.
The Zoetis Deal
- Landmark biologics agreement: A 10-year contract for commercial manufacturing of drug substance for Librela®, an injectable monoclonal antibody for osteoarthritis pain in dogs, with a total value of up to US$500 Mn over the life of the deal, subject to regulatory approvals and market demand.
- Strategic gateway: The agreement paves the way for development and manufacturing of other Zoetis molecules in coming years, marking a major strategic step for Syngene's biologics business.
- Revenue timing: The deal will start to benefit revenue in the second half of FY23 and build gradually in future years, with FDA and EMA regulatory approvals for Librela® anticipated later in 2022.
Hunt: "A recent highlight was the signing of a 10-year agreement with Zoetis. The new agreement initially focuses on the commercial manufacturing of Librela®, a first-of-its-kind injectable monoclonal antibody used for the alleviation of pain associated with osteoarthritis in dogs. This is a major strategic step for our biologics business and gives us a pathway towards FDA and EMA regulatory approvals anticipated later this year."
Revenue & Profitability
- Headline growth: Revenue from operations grew 8% YoY to ₹644 Cr, against a strong Q1 FY22 base that included Remdesivir sales during India's second COVID wave.
- Underlying momentum: Excluding Remdesivir, underlying revenue growth was approximately 30% YoY, reflecting strong performance across all business divisions.
- PAT decline: PAT declined 4% YoY to ₹74 Cr because the prior-year quarter benefited from strong Remdesivir sales; no Remdesivir sales were recorded in Q1 FY23.
- Sequential softening: Revenue declined 15% QoQ from Q4 FY22, with EBITDA down 29% and PAT down 50%, consistent with normal quarterly seasonality and the absence of one-off contributions.
- Margin contraction: EBITDA margin contracted to 28.5% from 29.2% YoY, with staff costs up 9% and other expenses up 57%, partly offset by a 14% decline in material and power costs reflecting the absence of Remdesivir-related raw material costs.
- Forex swing: Net foreign exchange swung from a 15.4 crore gain in Q1 FY22 to a 3.4 crore loss in Q1 FY23, a headwind of 18.8 crore.
Hunt: "These first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. ... The decline in profit in the quarter compared to the same period last year was as expected given the strong sales of Remdesivir last year when India was in the midst of the second wave of the pandemic. No sales of Remdesivir were recorded in the first quarter this year."
Divisional Performance
- Development and Manufacturing Services: Drove growth momentum against a low base in the previous year, supported by the establishment of a new kilo lab for polymer and specialty materials to shorten client development timelines.
- Dedicated Centers and Discovery Services: Delivered continued growth supported by a healthy demand environment, with Discovery Services benefiting from the commissioning of a PROTACs-focused lab in Hyderabad as part of the phase three Innopolis expansion, housing over 150 scientists and analysts.
- PROTACs capability: The new Hyderabad lab is dedicated to targeted protein degradation technology, part of Syngene's novel drug discovery strategy for clients involved in cancer treatment.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Raised from mid-teens to high teens, driven by rupee depreciation and the Zoetis agreement | FY23 |
| Zoetis revenue contribution | Revenue from Librela® commercial manufacturing to begin, subject to regulatory approvals | H2 FY23 |
| Zoetis regulatory approvals | FDA and EMA approvals for Librela® anticipated | Later in 2022 |
| Zoetis future molecules | Agreement paves the way for development and manufacturing of other molecules | Coming years |
Biswas: "Revenue guidance for the year has been raised from mid-teens to high teens to account for two factors: a significant change in the Rupee/US dollar exchange rate which helps the top line as most of our client contracts are dollar denominated and the recent agreement with Zoetis, which will start to benefit revenue in the second half of the year and build gradually in future years."
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue from operations | ₹644 Cr, +8% YoY |
| Total revenue | ₹660 Cr, +9% YoY |
| Underlying revenue growth (ex-Remdesivir) | ~30% YoY |
| EBITDA | ₹188 Cr, +6% YoY |
| EBITDA margin | 28.5%, vs 29.2% in Q1 FY22 |
| PAT | ₹74 Cr, -4% YoY |
| PAT margin | 11%, vs 13% in Q1 FY22 |
| EPS (basic) | ₹1.85 |
| Staff costs | ₹186 Cr, +9% YoY |
| Other expenses | ₹103 Cr, +57% YoY |
| Annual revenue growth guidance | High teens, raised from mid-teens |
| Zoetis agreement value | Up to US$500 Mn over 10 years, subject to regulatory approvals and market demand |
| Scientists | More than 5,200 |